Guangzhou Innogen Pharmaceutical Group Announces Proposed Implementation of H Share Full Circulation

Key Highlights of the Announcement

• Proposed Conversion of Domestic Unlisted Shares:
  Guangzhou Innogen Pharmaceutical Group Co., Ltd. has announced its intention to convert all of its domestic unlisted shares into H shares. This is a significant step towards expanding the liquidity and accessibility of its shares to international investors.
• Regulatory Filings Initiated:
  The Company submitted the filing application to the China Securities Regulatory Commission (CSRC) on 17 March 2026 for this conversion. The process is governed by the “Guidelines for the Application by H-share Companies for ‘Full Circulation’ of Unlisted Shares” and the “Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies”.
• Listing on Hong Kong Stock Exchange:
  Upon receiving all relevant approvals, the newly converted H shares will be listed and permitted to deal on the Main Board of the Hong Kong Stock Exchange. This move could significantly enhance the visibility and trading volume of the Company’s shares.
• No Further Shareholder Approval Required:
  Pursuant to the Company’s articles of association, no additional shareholders’ meeting is required to approve this conversion and listing process, streamlining the procedure.
• Pending Regulatory Approvals:
  The Company has not yet completed filing procedures with the CSRC, and the detailed implementation plan is still being finalized. The conversion and listing remain subject to further regulatory processes with both domestic and overseas authorities.
• Board Composition:
  The Board comprises a mix of executive, non-executive, and independent non-executive directors, led by Chairman Dr. Wang Qinghua.

Potentially Price Sensitive Information for Investors

• Increased Share Liquidity:
  The conversion of domestic unlisted shares into H shares is likely to significantly increase the liquidity and tradability of the Company’s shares. This could attract more institutional and international investors, potentially impacting share price positively.
• Regulatory Uncertainty:
  The process is not yet complete and is subject to regulatory approvals from the CSRC, the Hong Kong Stock Exchange, and other authorities. Any delays or issues in obtaining these approvals could impact the timeline and investor sentiment.
• Ongoing Announcements:
  The Company has committed to making further announcements as progress is made. Investors should monitor these updates closely as they may contain material information affecting share value.
• Shareholder Caution Advised:
  The Company specifically advises shareholders and potential investors to exercise caution when dealing in its shares during this period of regulatory uncertainty.

Additional Details

• The Company is acting under revised guidelines issued by the CSRC in November 2019, most recently amended in August 2023, and new administrative measures issued in February 2023.
• The conversion and listing will not require a further shareholders’ meeting, helping to expedite the process.
• The Board is led by Dr. Wang Qinghua and includes both executive and independent directors, ensuring a broad range of oversight.
• As of the date of the announcement, the Company has not completed all regulatory filings and has not finalized the implementation plan for the conversion and listing. The process is ongoing.

Conclusion

Guangzhou Innogen Pharmaceutical Group’s proposed conversion of all domestic unlisted shares into H shares and their listing on the Hong Kong Stock Exchange is a major corporate development. This move is likely to increase share liquidity and accessibility, potentially impacting the Company’s share price. However, as the process remains subject to regulatory approvals and is not yet finalized, shareholders and investors are urged to exercise caution and stay updated on further announcements from the Company.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. The proposed H share conversion and listing are subject to regulatory approvals and may not proceed as planned. Investors should monitor official announcements and consult their financial advisors before making any investment decisions.

View INNOGEN-B Historical chart here